Phase II clinical trial using anti-CD3 × anti-HER2 bispecific ...
This phase II trial evaluates the efficacy and immune responses of HER2 BATs given to patients with metastatic HER2-estrogen and/or progesterone receptor positive (HR+) and triple negative breast cancer (TNBC) as immune consolidation after chemotherapy.
A novel asymmetrical anti-HER2/CD3 bispecific antibody ...
Aug 14, 2019 · Human epidermal growth factor receptor 2 (HER2) is overexpressed in multiple cancers, which is associated with poor prognosis. Herceptin and other agents targeting HER2 have potent antitumor efficacy in patients with HER2-positive cancers.
A trispecific antibody targeting HER2 and T cells inhibits ...
Feb 23, 2022 · Here we demonstrate that a trispecific antibody to HER2, CD3 and CD28 stimulates regression of breast cancers in a humanized mouse model through a mechanism involving CD4-dependent inhibition of...
Precision-activated T-cell engagers targeting HER2 or EGFR ...
Mar 30, 2023 · A Biacore 4000 SPR biosensor (Cytiva) was used to measure binding kinetics of HER2-XPAT protein and its metabolites to the Fc-tag of the target ligands, human and cynomolgus monkey HER2 and CD3.
Phase II clinical trial using anti-CD3 x anti-HER2 bispecific ...
May 26, 2019 · Background: This study presents a phase II cell therapy trial in 32 women with metastatic or locally advanced HER2- breast cancer (BrCa) who received infusions of anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (BATs).
HER2/CD3 (WT-HER2 x CAB-CD3) bispecific antibody that binds with high affinity to recombinant CD3 and induces T cell activation under conditions that mimic the tumor microenvironment (acidic conditions), butwith lower affinity in physiological conditions (normal alkaline microenvironment).
A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal ...
Optimization of Her2/VEGFR2/CD3 tsAb results in enhanced T-cell-redirecting in vitro and in vivo antitumor efficacy compared with the corresponding bsAbs alone or in combination, and the potency to overcome tumor relapse due to antigen escape or resistance to Herceptin and Cyramza therapy.